AKT1 and acute myeloid leukemia: While pan-PIM inhibitor AZD1897 showed limited activity as monotherapy in AML cell lines and primary samples, including FLT3-ITD+ cells, combination of AZD1897 with Akt inhibitor AZD5363 displayed synergistic anti-leukemic activity [293].